Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385471 | 1.00 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17570969 | 0.89 | CA1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31385500 | 0.86 | MRGPRX4 (0.63) | MRGPRX4 | |
| SCHEMBL17615247 | 0.85 | CA1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23017630 | 0.82 | NOTUM (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4402201 | 0.82 | ALDH1A1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7019854 | 0.82 | MAPT (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31385499 | 0.82 | NOTUM (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20868558 | 0.81 | IDO1 (0.48) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL19140032 | 0.80 | PSEN1 (0.41) | MRGPRX4MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | CA12 3902/4885CA1 3251/4885CA2 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.